Enanta Pharmaceuticals, Inc. (ENTA)

Enanta Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021
Cash & Equivalents	32.3	37.23	85.39	43.99	57.21
Short-Term Investments	156.57	210.95	284.52	205.24	186.8
Cash & Short-Term Investments	188.86	248.19	369.91	249.23	244
Cash Growth	-23.90%	-32.91%	48.42%	2.14%	-36.89%
Accounts Receivable	6.88	6.65	8.61	20.32	23.58
Other Receivables	-	32	31	28.72	37.26
Receivables	6.88	38.65	39.62	49.04	60.83
Prepaid Expenses	8.59	12.41	13.26	13.45	14.19
Restricted Cash	-	0.61	-	-	-
Total Current Assets	204.34	299.85	422.79	311.71	319.02
Property, Plant & Equipment	72.94	73.35	34.71	29.75	10.65
Long-Term Investments	-	-	-	29.29	108.42
Other Long-Term Assets	3.45	3.45	4.77	4.66	0.7
Total Assets	280.73	376.65	462.28	375.41	438.79
Accounts Payable	1.95	8	4.1	6	9.54
Accrued Expenses	12.75	13.55	18.34	20.94	22.43
Current Portion of Long-Term Debt	30.71	34.46	35.08	-	-
Current Portion of Leases	3.15	1.52	5.28	2.89	4.2
Total Current Liabilities	48.56	57.54	62.79	29.83	36.17
Long-Term Debt	112.44	136.13	160.85	1.42	1.51
Long-Term Leases	54.76	53.94	21.24	22.37	1.13
Other Long-Term Liabilities	0.26	0.23	0.66	0.45	0.56
Total Liabilities	216.02	247.84	245.54	54.08	39.36
Common Stock	0.21	0.21	0.21	0.21	0.2
Additional Paid-In Capital	469.77	451.34	424.69	398.03	351.03
Retained Earnings	-404.93	-323.04	-207	-73.18	48.58
Comprehensive Income & Other	-0.34	0.3	-1.17	-3.72	-0.38
Shareholders' Equity	64.72	128.81	216.74	321.33	399.43
Total Liabilities & Equity	280.73	376.65	462.28	375.41	438.79
Total Debt	201.06	226.06	222.44	26.69	6.84
Net Cash (Debt)	-12.19	22.13	147.47	251.83	345.58
Net Cash Growth	-	-85.00%	-41.44%	-27.13%	-15.65%
Net Cash Per Share	-0.57	1.05	7.03	12.22	17.13
Filing Date Shares Outstanding	28.86	21.19	21.06	20.8	20.32
Total Common Shares Outstanding	21.39	21.19	21.06	20.79	20.24
Working Capital	155.78	242.32	360	281.89	282.85
Book Value Per Share	3.03	6.08	10.29	15.46	19.74
Tangible Book Value	64.72	128.81	216.74	321.33	399.43
Tangible Book Value Per Share	3.03	6.08	10.29	15.46	19.74
Machinery	20.39	19.92	19.14	16.79	16.32
Construction In Progress	-	22.75	1.27	2.56	0.02
Leasehold Improvements	38.2	13.98	13.8	7.28	7.14

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q